Chronic Lymphocytic Leukemia

Barr Evaluates BTK Inhibitors for Treating Frontline CLL

August 29, 2020

During a virtual Case Based Peer Perspectives event, Paul M. Barr, MD, reviewed the case of a 71-year-old woman with newly diagnosed chronic lymphocytic leukemia and the role of BTK inhibitors in the frontline setting.

COVID-19 Severity in CLL Correlates With 3 Disease Characteristics

August 18, 2020

The severity of coronavirus disease 2019 increases with age in patients with chronic lymphocytic leukemia. However, age and the existence of comorbidities may not impact death from COVID-19, according to results from a retrospective international study.

Ibrutinib Plus Umbralisib Induce Survival Benefit in Patients With CLL

August 17, 2020

Matthew Davids, MD, MMSc, discusses the longer-term follow-up data from the phase 3 UNITY-CLL clinical trial, which evaluated umbralisib in combination with ibrutinib as treatment of patients with chronic lymphocytic leukemia.

Coutre Evaluates Treatment Options in Relapsed/Refractory CLL

August 13, 2020

During a virtual Case Based Peer Perspectives event, Steven Coutre, MD, reviewed a case of a 53-year-old woman who first presented with elevated white blood cell count. The patient was later diagnosed with chronic lymphocytic leukemia.